Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)

NCT07480213 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer (SCLC)
Relapsed/Refractory SCLC
SCLC, Extensive Stage

Interventions

BIOLOGICAL: EB-DART-NK01 (DLL3/CD56 CAR-NK cells)
DRUG: Lymphodepleting chemotherapy

Sponsor

Beijing Biotech